Trial Profile
Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
- 15 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 Mar 2017 New trial record